Publications
Detailed Information
Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Xu, Binghe | - |
dc.contributor.author | Li, Wei | - |
dc.contributor.author | Robson, Mark | - |
dc.contributor.author | Ouyang, Quchang | - |
dc.contributor.author | Yeh, Dah-Cherng | - |
dc.contributor.author | Iwata, Hiroji | - |
dc.contributor.author | Park, Yeon Hee | - |
dc.contributor.author | Sohn, Joo Hyuk | - |
dc.contributor.author | Tseng, Ling-Ming | - |
dc.contributor.author | Goessl, Carsten | - |
dc.contributor.author | Wu, Wenting | - |
dc.contributor.author | Masuda, Norikazu | - |
dc.date.accessioned | 2022-03-22T09:21:54Z | - |
dc.date.available | 2022-03-22T09:21:54Z | - |
dc.date.created | 2020-10-27 | - |
dc.date.created | 2020-10-27 | - |
dc.date.created | 2020-10-27 | - |
dc.date.created | 2020-10-27 | - |
dc.date.created | 2020-10-27 | - |
dc.date.issued | 2020-05 | - |
dc.identifier.citation | Scientific Reports, Vol.10 No.1, p. 8753 | - |
dc.identifier.issn | 2045-2322 | - |
dc.identifier.other | 113987 | - |
dc.identifier.uri | https://hdl.handle.net/10371/177259 | - |
dc.description.abstract | The OlympiAD Phase III study (NCT02000622) established the clinical benefits of olaparib tablet monotherapy (300mg twice daily) over chemotherapy treatment of physician's choice (TPC) in patients with a germline BRCA1/2 mutation (gBRCAm) and human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who had received <= 2 chemotherapy lines in the metastatic setting. Here, we report pre-specified analyses of data from Asian (China, Japan, Korea and Taiwan) patients in the study. All patients were randomized 2:1 to olaparib tablets (300mg twice daily) or single-agent chemotherapy TPC (21-day cycles of either capecitabine, eribulin or vinorelbine). The primary endpoint was progression-free survival assessed by blinded independent central review. The prevalence of gBRCAm in the OlympiAD Asian subgroup screened for study recruitment was 13.5%. Patient demographics and disease characteristics of the Asian subgroup (87/302 patients) were generally well balanced between treatment arms. Asian patients in the olaparib arm achieved longer median progression-free survival, assessed by blinded independent central review, versus the chemotherapy TPC arm (5.7 vs 4.2 months; HR=0.53 [95% CI: 0.29-0.97]), which was consistent with findings in the global OlympiAD study population. Findings on secondary efficacy and safety/tolerability outcome measures in Asian patients were also similar to those observed in the global OlympiAD study population. The OlympiAD study was not powered to detect race-related differences between treatment groups; however, the consistency of our findings with the global OlympiAD study population suggests that previously reported findings are generalizable to Asian patients. | - |
dc.language | 영어 | - |
dc.publisher | Nature Publishing Group | - |
dc.title | Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.1038/s41598-020-63033-4 | - |
dc.citation.journaltitle | Scientific Reports | - |
dc.identifier.wosid | 000560076900003 | - |
dc.identifier.scopusid | 2-s2.0-85085715184 | - |
dc.citation.number | 1 | - |
dc.citation.startpage | 8753 | - |
dc.citation.volume | 10 | - |
dc.identifier.sci | 000560076900003 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Im, Seock-Ah | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.